Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis

Summary

This multicentre proof-of-concept study, involving 4 centers, aims to establish the value of fractionated neoadjuvant stereotactic radiotherapy (NaSRT) as a new treatment paradigm for brain metastases (BM) in the frame of the Czech neurooncology network. Most relevant studies published to date used single-fraction radiotherapy and dealt with the inherent bias related to their retrospective nature. The researchers aim to increase the level of evidence for this treatment paradigm together with other similar ongoing studies.

Eligibility

Inclusion Criteria:

* Age ≥ 18 years
* Karnofsky Performance Status ≥ 60
* Histologically verified primary cancer disease
* MRI findings indicating BM
* Target BM indicated for surgical resection and any other metastases suitable for radical SRT.
* Target BM between 1 cm and 7 cm at the longest diameter on T1 post-contrast MR imaging

Exclusion Criteria:

* Confirmed hematological malignity
* Small-cell (lung) carcinoma
* Peracute condition requiring immediate neurosurgical intervention
* History of whole-brain radiotherapy (WBRT)
* History of stereotactic radiotherapy to a target brain metastasis
* Pregnancy
* Inability to perform surgical resection of the target BM within 7 days after NaSRT

Conditions2

Browse More Trials